How a Vaccine Trial Transformed My Perspective on Cancer

Cancer has been a defining part of my journey, one that has tested my strength, reshaped my outlook, and ultimately inspired my commitment to research and advocacy. I am a three-time cancer survivor, having faced colorectal, endometrial and basal cell carcinoma, all connected to Lynch Syndrome, a hereditary genetic condition that increases cancer risk throughout an individual’s lifetime.

Each diagnosis was life-altering. My first cancer, colorectal, arrived without warning and introduced me to a new world of medical language, procedures and decisions. When endometrial cancer followed, I began to recognize patterns and questions that connected my experiences. By the time I was diagnosed with basal cell carcinoma, I knew this wasn’t coincidence. There was something deeper at play.

That search for understanding led to the discovery through genetic testing, that I carried an MSH2 gene mutation, confirming Lynch Syndrome. While the diagnosis was daunting, it gave me clarity and purpose. Knowing the “why” behind my cancers motivated me to learn more, to ask questions and to engage directly with research that could change outcomes for people like me.

Becoming an advocate was a natural next step. I began sharing my story, connecting with patient organizations and joining advisory panels focused on hereditary cancers. I saw firsthand how powerful patient voices could be when shaping research priorities and influencing care. But my perspective shifted profoundly when I became a participant in a clinical trial for a Lynch Syndrome vaccine, a moment that connected my personal experience with the broader scientific mission to prevent cancer.

When I first learned about the vaccine trial, I felt both hopeful and hesitant. Participating meant stepping into the unknown once again, but this time, not as a patient fighting disease but as a partner contributing to discovery. The trial aimed to develop a vaccine that could help the immune system recognize and attack cells with the DNA mismatch repair deficiencies characteristic of Lynch Syndrome. For me, that wasn’t just science, it was personal.

Through the clinical trial, I witnessed collaboration in its most meaningful form. Researchers, clinicians and participants worked together toward a common goal, prevention. I saw the dedication of scientists who believed in the power of partnership and the critical role that patient engagement plays in research. I also experienced the human side of clinical trials: the trust, communication, and shared sense of purpose that binds everyone involved.

Participating in the Lynch Syndrome vaccine trial didn’t just give me hope; it redefined how I think about cancer. For years, I viewed cancer as something to survive, an enemy to endure and overcome. Now, I see it as a catalyst for change and innovation. Every data point, every tissue sample, every story like mine contributes to the collective knowledge that brings us closer to prevention and cure.

My role as a patient and research advocate has evolved from storyteller to stakeholder. I work to ensure that patients, especially those from diverse and underrepresented backgrounds, have access to clinical trials and that their experiences inform research from start to finish. Advocacy is not only about awareness; it’s about action. It’s about creating systems that include patient insights as essential data in the pursuit of better science.

Cancer has taken much from me, but it has also given me purpose and a platform. Through advocacy and participation, I’ve come to understand that the future of cancer care depends on collaboration between patients and scientists, between research and real life. My experience in the Lynch Syndrome vaccine trial reinforced my belief that patients are not just participants in research, they are partners, driving innovation through lived experience.

Today, I carry that message into every space I’m in: research meetings, advocacy boards and patient communities. Because every trial, every story and every act of engagement brings us closer to a world where cancer prevention is possible.

For me, hope is no longer just surviving another diagnosis, it’s helping create a future where fewer people will ever have to face one.

Wenora Johnson is a three-time cancer survivor, patient and research Advocate, and a carrier of Lynch Syndrome (MSH2 mutation). She collaborates with research organizations, advocacy groups and clinical teams to promote equitable patient engagement and awareness of hereditary cancers. Wenora is passionate about ensuring that diverse patient perspectives inform research, policy, and the next generation of cancer prevention strategies.

This piece reflects the author’s personal experience and perspective. For medical advice, please consult your health care provider.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.